#VisualAbstract: Semaglutide Improves Outcomes in Patients with Obesity-Related Heart Failure and Type 2 Diabetes
Click here to to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be ...
Tag: HFpEF (heart failure with preserved ejection fraction
Semaglutide improves symptoms and function in obesity-related heart failure
1. Semaglutide showed significant improvements in KCCQ-CSS score and reduction in body weight compared to placebo. 2. There were fewer ...
Sodium-glucose cotransporter-2 inhibitors are of intermediate or low economic value in the treatment of heart failure with preserved ejection fraction
1. Sodium-glucose cotransporter-2 inhibitors (SGLT2-I) in combination with standard of care were found to increase quality-adjusted life-years at a cost ...
Moderately accelerated cardiac pacing may be beneficial in patients with heart failure with preserved ejection fraction
1. Quality of life at one year was improved in patients with heart failure with preserved ejection fraction (HFpEF) who ...
Dapagliflozin associated with reduction in cardiovascular mortality due to lower rates of death from heart failure and sudden death – Pooled analysis of DAPA-HF and DELIVER
1. In this pooled analysis of 11,007 patients with heart failure in the DAPA-HF and DELIVER trials, treatment with dapagliflozin ...
#VisualAbstract: Dapagliflozin slows disease progression in patients with heart failure with preserved ejection fraction
1. Dapagliflozin was shown to reduce the risk of disease progression and cardiovascular death in patients with a mildly reduced ...
Dapagliflozin slows disease progression in patients with heart failure with preserved ejection fraction
1. Dapagliflozin was shown to reduce the risk of disease progression and cardiovascular death in patients with a mildly reduced ...
Simple score developed to predict increased risk of transthyretin amyloid cardiomyopathy in patients with heart failure with preserved ejection fraction
1. The simple score comprised of 3 clinical (age, male sex, hypertension diagnosis) and 3 echocardiographic (ejection faction, posterior wall ...
SGLT-2 inhibitors provide morbidity and mortality benefits for patients with heart failure
1. SGLT-2 inhibitors reduced time to first hospitalization and cardiovascular death among patients with preserved, mildly reduced, and reduced ejection ...
Sacubitril or valsartan versus standard medical therapies in patients with heart failure with preserved ejection fraction: PARALLAX trial
1. In this randomized, controlled trial, for patients with heart failure and left ventricular ejection fraction higher than 40%, sacubitril/valsartan ...